Continuous glucose monitors help type 2 diabetes patients spend 5 more hours a day in healthy blood sugar range
Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine.
A new study published in the New England Journal of Medicine reveals that continuous glucose monitors (CGMs) can significantly improve blood sugar management for adults with type 2 diabetes who do not take insulin. The clinical trial, involving 283 participants across 22 U.S. primary care practices, found that CGM users spent approximately five more hours each day within their target blood sugar range compared to those receiving routine care.
Additionally, CGM users achieved an A1c level below 7% more frequently, a common treatment goal for people with diabetes. The study's lead author, Dr. Tamara Oser, emphasized the importance of improving care for the millions of Americans with type 2 diabetes who do not take insulin, as elevated blood sugar can increase the risk of serious health complications.
The trial, the first large-scale, multicenter randomized controlled study of CGMs in this population, provides robust evidence supporting the use of CGMs in this group, potentially influencing national diabetes care guidelines and insurance coverage.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
